F-star bought out in $161M all-cash deal as Hong Kong's Sino Biopharm looks toward international expansion
After more than a decade and a half of charting its own course, F-star Therapeutics will now settle under a new umbrella company.
The UK biotech will be acquired by invoX Pharma, a subsidiary of Hong Kong’s Sino Biopharm, in a roughly $161 million all-cash deal, the companies announced Thursday morning. F-star’s buyout will value its shares $FSTX at $7.12 apiece, nearly an 80% premium above Wednesday’s closing price.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.